Severity Staging of Chronic Obstructive Pulmonary Disease: Differences in Pre- and Post-Bronchodilator Spirometry
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease (COPD) uses the post-bronchodilator spirometry for diagnosis and severity staging. We evaluated differences in the severity classification of COPD, based on pre- and post-bronchodilator spirometry. Materials and Methods: From 2000 to 2004, 207 COPD patients who underwent spirometry before and after inhalation of 400 μg of fenoterol were analyzed. A responder to the bronchodilator test (BDT) was defined by the American Thoracic Society (ATS) as an increase in forced expiratory volume in one second (FEV1) or forced vital capacity ≥ 12% and ≥ 200 mL, and by the European Respiratory Society (ERS) as an increase in FEV1 ≥ 10% of the predicted value. COPD severity was classified according to the 2008 GOLD guidelines. Results: For the entire study population, the FEV1 increased by 11.8 ± 12.5% of baseline after BDT and 41.1% and 27.1% of subjects were classified as responders using the ATS and ERS criteria, respectively. Based on pre-BDT spirometry, 55, 85, 58, and 9 patients were classified as Stage I-IV COPD, respectively. Sixty-seven (32.4%) patients changed severity staging after BDT, including 20.0%, 28.2%, 44.8%, and 66.7% of pre-BDT patients Stages I through IV, respectively. More ATS or ERS BDT-responders had a change in severity staging than non-responders (52.9% vs. 18.9% and 62.5% vs. 21.2%, both p < 0.001). Conclusion: Our data suggest that the severity staging of COPD using pre-BDT spirometry might lead to significant differences as compared to staging, based on post-BDT spirometry, as recommended by the current GOLD guidelines.
Abstract
Purpose: The Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines for chronic obstructive pulmonary disease (COPD) uses the post-bronchodilator spirometry for diagnosis and severity staging. We evaluated differences in the severity classification of COPD, based on pre- and post-bronchodilator spirometry. Materials and Methods: From 2000 to 2004, 207 COPD patients who underwent spirometry before and after inhalation of 400 μg of fenoterol were analyzed. A responder to the bronchodilator test (BDT) was defined by the American Thoracic Society (ATS) as an increase in forced expiratory volume in one second (FEV1) or forced vital capacity ≥ 12% and ≥ 200 mL, and by the European Respiratory Society (ERS) as an increase in FEV1 ≥ 10% of the predicted value. COPD severity was classified according to the 2008 GOLD guidelines. Results: For the entire study population, the FEV1 increased by 11.8 ± 12.5% of baseline after BDT and 41.1% and 27.1% of subjects were classified as responders using the ATS and ERS criteria, respectively. Based on pre-BDT spirometry, 55, 85, 58, and 9 patients were classified as Stage I-IV COPD, respectively. Sixty-seven (32.4%) patients changed severity staging after BDT, including 20.0%, 28.2%, 44.8%, and 66.7% of pre-BDT patients Stages I through IV, respectively. More ATS or ERS BDT-responders had a change in severity staging than non-responders (52.9% vs. 18.9% and 62.5% vs. 21.2%, both p < 0.001). Conclusion: Our data suggest that the severity staging of COPD using pre-BDT spirometry might lead to significant differences as compared to staging, based on post-BDT spirometry, as recommended by the current GOLD guidelines.
참고문헌 (26)
- "Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease", NHLBI, 2008, ~[DOI]
- Celli BR, "The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease", N Engl J Med, 350, pp.1005~1012 (2004)
- O’Donnell RA, "Relationship between peripheral airway dysfunction, airway obstruction, and neutrophilic inflammation in COPD", Thorax, 59, pp.837~842 (2004)
- Lapperre TS, "Dissociation of lung function and airway inflammation in chronic obstructive pulmonary disease", Am J Respir Crit Care Med, 170, pp.499~504 (2004)
- Doi M, "Significance of pulmonary artery pressure in emphysema patients with mild-to- moderate hypoxemia", Respir Med, 97, pp.915~920 (2003)
- Antonelli-Incalzi R, "Do GOLD stages of COPD severity really correspond to differences in health status?", Eur Respir J, 22, pp.444~449 (2003)
- Morris A, "Association of chronic obstructive pulmonary disease severity and Pneumocystis colonization", Am J Respir Crit Care Med, 170, pp.408~413 (2004)
- Hogg JC, "The nature of small-airway obstruction in chronic obstructive pulmonary disease", N Engl J Med, 350, pp.2645~2653 (2004)
- Donohue JF, "Therapeutic responses in asthma and COPD, in Bronchodilators", Chest, 126, pp.125S~137S (2004)
- Sterk PJ, "Let’s not forget: the GOLD criteria for COPD are based on post-bronchodilator FEV1", Eur Respir J, 23, pp.497~498 (2004)
- "Standardization of spirometry--1987 update, in Statement of the American Thoracic Society", Am Rev Respir Dis, 136, pp.1285~1298 (1987)
- "Lung function testing: selection of reference values and interpretative strategies, in American Thoracic Society", Am Rev Respir Dis, 144, pp.1202~1217 (1991)
- Siafakas NM, "Optimal assessment and management of chronic obstructive pulmonary disease (COPD). The European Respiratory Society Task Force", Eur Respir J, 8, pp.1398~1420 (1995)
- Yang SC, "Re-evaluation of the ventilatory function in a normal Chinese: comparison with the results of a survey conducted 15 years ago", J Formos Med Assoc, 92(3), pp.S152~S159 (1993)
- Perng DW, "Characteristics of airway inflammation and bronchodilator reversibility in COPD: a potential guide to treatment", Chest, 126, pp.375~381 (2004)
- Reid DW, "Bronchodilator reversibility in Australian adults with chronic obstructive pulmonary disease", Intern Med J, 33, pp.572~577 (2003)
- Quadrelli SA, "Evaluation of bronchodilator response in patients with airway obstruction", Respir Med, 93, pp.630~636 (1999)
- Calverley PM, "Bronchodilator reversibility testing in chronic obstructive pulmonary disease", Thorax, 58, pp.659~664 (2003)
- Sourk RL, "Bronchodilator testing: confidence intervals derived from placebo inhalations", Am Rev Respir Dis, 128, pp.153~157 (1983)
- Huchon G, "Comparison of the safety of drug delivery via HFA- and CFC-metered dose inhalers in CAO", Eur Respir J, 15, pp.663~669 (2000)
- Hodder R, "Low incidence of paradoxical bronchoconstriction in asthma and COPD patients during chronic use of Respimat soft mist inhaler", Respir Med, 99, pp.1087~1095 (2005)
- Roncoroni AJ, "Bronchoconstriction induced by repeated forced vital capacity manoeuvres", Acta Allergol, 30, pp.375~389 (1975)
- Hubbard R, "Use of inhaled corticosteroids and the risk of fracture", Chest, 130, pp.1082~1088 (2006)
- Lee TA, "Fracture risk associated with inhaled corticosteroid use in chronic obstructive pulmonary disease", Am J Respir Crit Care Med, 169, pp.855~859 (2004)
- Hansen EF, "Reversible and irreversible airflow obstruction as predictor of overall mortality in asthma and chronic obstructive pulmonary disease", Am J Respir Crit Care Med, 159, pp.1267~1271 (1999)
- Chanez P, "Corticosteroid reversibility in COPD is related to features of asthma", Am J Respir Crit Care Med, 155, pp.1529~1534 (1997)